The Egyptian Journal of Hospital Medicine (July 2022) Vol. 88, Page 3637-3645

Modern Diagnostic and Therapeutic Options for Retroperitoneal Fibrosis; Review article

Mohammed Raafat Hassan Mohammed*, Mostafa Mohmmad Mohammad Ebraheem Rashed, Mahmoud Saeed Mahmoud Ibrahem

Urology department, Ahmed Maher Teaching Hospital, Cairo, Egypt
***Corresponding author:** Mohammed Raafat Hassan Mohammed

E-mail: mohammed.rafaat1983@gmail.com , Mobile phone: 01009291394

ABSTRACT

Background: Retroperitoneal fibrosis (RPF) is a rare condition characterized by inflammation and fibrous tissue deposition in the abdomen surrounding the aorta. This process has the potential to spread to nearby tissues, resulting in several complications, the most common and serious of which is a ureteral blockage.

The most common cause is idiopathic retroperitoneal fibrosis (IRF), on the other hand, it can also be due to a variety of other elements. However, the illness's main cause is still unknown. In retroperitoneal fibrosis, it surrounds the aorta and common iliac artery causing ureteral obstruction. Secondary spread of retroperitoneal fibrosis has been linked to malignant illness, medications, radiation exposure, and surgery.

The predominance of retroperitoneal fibrosis is categorized as idiopathic, which is caused by an immune response. Idiopathic retroperitoneal fibrosis is nowadays thought to be a component of the illness group linked to immunoglobulin G4, a systemic inflammatory disease whose concept was only recently proposed.

Conclusion: According to current research, over half of all instances of IRF might be due to newly found, illnesses linked to immunoglobulin G4 that are medically varied (IgG4-RD). Corticosteroid medications will be the first therapy for IRF, however, immunosuppressant drugs are also active therapy. This research adds a new understanding of concepts about etiopathogenesis, clinical manifestations, diagnosis, and therapy options for various forms of RPF.

Keywords: Retroperitoneal fibrosis, chronic periaortitis, immunoglobulin G4-related sickness, and systemic inflammatory disease.

INTRODUCTION

Retroperitoneum fibrosis remains a rare illness characterized by an inflammatory response and the gross of fibrous tissue surrounding the aorta and iliac arteries in the abdomen, which frequently expands beyond the retroperitoneum region and affects nearby organs [(1)].

Idiopathic (idiopathic retroperitoneal fibrosis – IRF), which affects around two-thirds of diseased persons, or is connected to malignancies, drugs, infections, traumas, radiation, or surgery might be the cause of this condition. IRF may be a marker of a recent, clinically diverse IgG4-related disease in around half of the persons, according to current statistics [(2)].

Idiopathical retroperitoneal fibrosis (IRF) is a group of illnesses in which fibro-inflammatory tissue covers the aortic artery and iliac arteries in the abdomen. This infection has the potential to expand to the retroperitoneum, devouring nearby organs such as the ureters. Retroperitoneal fibrosis is a rare disease that affects 1.38 people in every100, 000., Although medicinal medications, infections, malignancies, injuries, surgical operations, and irradiation exposure, are being identified as secondary causes of this condition, idiopathic affection continues to be the most common. Imaging studies and histology are utilized to diagnose IRF and rule out other illnesses such as malignancy. Periureteral involvement causes acute renal failure. In particular, it needs immediate care. The most popular treatments are corticosteroids, which can be used alone or in conjunction with other immunomodulation medications, or tamoxifen. If periureteral or perivascular involvement is found, surgery may be indicated [(3)].

In retroperitoneal fibrosis, fibrotic lesions around the aorta and common iliac artery induce ureteral obstruction. Secondary retroperitoneal fibrosis has been associated with malignant sickness, medications, radiation exposure, and surgery.

Idiopathic retroperitoneal fibrosis, which has an immunological cause, is the most common kind of retroperitoneal fibrosis. Idiopathic retroperitoneal fibrosis is now thought to be a component of an immunoglobulin G4-related sickness, a systemic inflammatory disease first proposed a decade ago. In the treatment of retroperitoneal fibrosis, systemic lesions linked with immunoglobulin G4-related disease, as well as the exclusion of future retroperitoneal fibrosis, must be investigated [(4)].

The therapeutic application of retroperitoneal fibrosis is the main goal and had better to remove the stent/nephrostomy and restore renal function while also removing the glucocorticoid; however, caution may not always yield positive results. An offensive surgical treatment, for example, ureterolysis, may accomplish the aim, but it comes with a substantial risk of

Received: 16/3/2022
Accepted: 15/5/2022

morbidity. A consensus on the optimum management for idiopathic retroperitoneal fibrosis, as well as the best suggestions for aggressive surgery and conventional care, would be excellent [5].

The current paper summarises existing RPF knowledge and analyses the most effective diagnostic and therapy methods. Epidemiology: Here's some information from Finland on the epidemiology of retroperitoneum fibrosis. Epidemiologic information on RPF is scarce.

The anniversary prevalence rate was initially thought to be approximately 0.1 per 100,000 persons, whereas RPF is estimated to be around 1.4 per 100,000 people. Subsequent research by van Bommel et al. reveals a 13-fold increase (1,3/100,000 persons).

The widespread availability of more sensitive diagnostic technologies may be to blame for this breakthrough in diagnosis. RPF is most common in people in their 50s and 60s, but it can also strike children and teenagers. Men are 2–3 times as likely to be affected as women [6].

Aetiopathogenesis:

Idiopathical retroperitoneal fibrosis is one of three types of chronic periaortitis (CP), which is marked by the deposition of fibro-inflammatory peri-aortic materials within the retroperitoneum.

Chronic periaortitis can be caused by a dilated or non-dilated aorta.

The aorta is normal in IRF, but the fibrotic mass might migrate and entrap Surrounding tissues. One type of aneurysmal CP is an inflammation of the abdominal aorta, which results in an IAAA, and another is perianeurysmal retroperitoneal fibrosis (PRF), which involves the surrounding tissues as well.



Figure 1: Retroperitoneal Fibrosis [7]

The following is the RPF classification:

Secondary RPF type:

Malignant illness was thought to be the main cause of secondary RPF for a long period. Despite the clinical similarities, the etiology of malignancy-related secondary RPF differs from that of other secondary RPF. The ureter is impacted when a malignant tumor, including primary, and widespread disease are present rather than benign reactive inflammatory tissue. Although malignant lymphoma is the most common cancer associated with RPF, it can also be caused by solid cancer metastases and spread from distant areas such as the breast, stomach, or pancreas [(8)].

Secondary RPF-induced hydronephrosis might be the only evidence of a recurrence of malignant disease. Secondary RPF is commonly caused by peritoneal spreading, which does not necessarily result in radiographically apparent nodular lesions and ascites [(8)]

Physicians should look for the possibility of RPF recurrence in cancer patients who have already been treated. Secondary RPF caused by the malignant disease may be eased by treating the underlying ailment, depending on how effective the treatment is. After temporal indwelling, the stent or PNS may be withdrawn in most cases.

Such a clinical history is predicted in malignant lymphoma, which is a prevalent primary illness. The most common causative substances are ergot alkaloid derivatives like methysergide and ergotamine. Secondary RPF has also been linked to infectious organisms such as Mycobacterium TB and Actinomyces. Radiation and surgery for retroperitoneal affections may induce fibrosis, which can lead to ureteral blockage [(9)].

Idiopathic RPF:

Idiopathic RPF is RPF that develops for no obvious reason. Over 70% of RPF cases are classed as idiopathic, which indicates that there is no known cause. Chronic periaortitis, inflammatory AAA, and perianeurysmal fibrosis are all examples of idiopathic RPF. The term "chronic periaortitis" is typically used since the thoracic aorta is usually afflicted (idiopathic RPF, on the other hand, does not necessarily develop around the aorta). Patients with aneurysms are diagnosed with "inflammatory AAA" or "perianeurysmal fibrosis," both of which look and feel like idiopathic RPF without aneurysms. A clinical feature of idiopathic RPF has enhanced response to glucocorticoid treatment [(10)].

Since the 1990s, an autoimmune mechanism has been proposed as a possible explanation for idiopathic RPF. In the twenty-first century, similar histology results for additional autoimmune illnesses, such as autoimmune pancreatitis, were documented [(11)].

In the past two decades, the concept of IgG4RD has emerged, in which IgG4RD is an autoimmune illness characterized by IgG4-positive plasma cells infiltrating multi organs or tissues, such as the lachrymal and salivary glands (Mikulicz disease), pancreas, bile duct, thyroid, hypophysis, kidney, prostate, orbit, and retroperitoneum [(11)].

The majority of idiopathic RPF patients now fall under this illness range. According to a histology study, IgG4RD accounts for at least half of all idiopathic RPF cases, with the remainder being "IgG4-unrelated".

Vaglio et al., on the other hand, believe that both disorders are symptoms of the same disease, IgG4RD. Although IgG4RD is typically a total infection that affects many organs, there have been instances of IgG4RD affecting only the retroperitoneum with no extraperitoneal lesions. As a result, IgG4RD in the retroperitoneum and IgG4-unrelated idiopathic RPF have sparked discussion [(12)].

IgG4-related disease:

In the 1990s, several disorders involving IgG4-positive plasma cells invading multiple systems were discovered, and each organ's disease was characterized individually. For a definite diagnosis of IgG4RD, histological investigation is necessary, per the criteria. Retroperitoneal lesions, on the other hand, necessitate a more intrusive biopsy than the salivary and lachrymal glands. Histological testing is usually avoided in individuals with high blood IgG4 levels and no extraretroperitoneal lesion large enough for biopsy. Patients with abnormal radiographic results should have a biopsy performed [(13)].

FDG-PET/CT can be used to locate IgG4-RD lesions and determine the best biopsy location, as well as track disease progression and therapeutic response.

Although the procedure has not been standardized, IgG4RD typically reacts effectively and quickly to glucocorticoid therapy. Long-term maintenance with 2.5–5 mg of PSL is required in normal IgG4RD since the illness is prone to return, resulting in implicated organ failure upon drug withdrawal.

Table I: Diagnostic criteria for IgG4-RD [(14)]

Criteria	Diagnosis		
	Definite	**Probable**	**Possible**
1. Characteristic diffuse/localized swelling or masses present in single or multiple organs	+	+	+
2. Increased concentrations of IgG4 in serum (> 135 mg/dl)	+	–	+
3. Histopathological picture: a. marked lymphocyte and plasmacyte infiltration with fibrosis b. infiltration of IgG4-positive plasma cell: ratio of IgG4/IgG-positive cells > 40% and > 10 IgG4-positive plasma cells per high power field	+	+	–

A definite diagnosis can be made when all three criteria while excluding a proliferative process and other diseases, are met. The diagnosis is probable if criteria 1 and 3 are met, and possible if criteria 1 and 2 are fulfilled

Symptoms:

Retroperitoneal fibrosis progresses slowly since the initial symptoms are non-specific. The more popular symptoms are back aching, flank pain, or pain of the abdomen, which frequently radiates along the pelvic region with/or without the side of the lower leg.

The pain is pronounced dull and continuous, and it doesn't go away even when you're sleeping. Non-steroidal anti-inflammatory medicines provide immediate relief, however, this is just a short impact. When the ureters are encased, the discomfort may be similar to colic.

Patients frequently complain of constipation, and duodenal involvement can lead to obstruction. To mention a few symptoms, compression of the lymphatic arteries and veins positioned retroperitoneally causes edema and thrombosis of the deep vein in the legs, scrotal enlargement, testicular discomfort, varicocele, and hydrocele. Atherosclerosis symptoms include renal-vascular elevated pressure, intermittent claudication, and ischemic intestine [(15)].

Patients may develop constitutional symptoms in addition to weariness, fever, weight loss, appetite loss, and muscle and joint stiffness. The physical examination only plays a minor role in the diagnosis. Through the abdominal wall, a fibrous mass that causes lumbar or abdominal discomfort can be felt [(16)].

Because the clinical picture isn't always clear, it often takes longer between the start of symptoms and a clear diagnosis, which increases the risk of serious fibrosis problems. Hydronephrosis, which is caused by a blocked ureter, is the most common and dangerous side effect. It affects 47–100% of patients [(17)]. It is bilateral in more than half of the instances.

RPF diagnostic approach:

In individuals with clinical signs of RPF and ureteral obstruction, proper diagnosis and categorization are required since treatment approaches differ significantly depending on the illness [(18)].

Assessment of ureteral disease and salvage of renal function:

People who have symptoms of RPF and ureteral blockage should be checked for intraureteral disorders such as ureteral malignancy. Urinary cytology and retrograde pyelography are further tests that are advised. If more ureteral stenting is required to save renal function, it should be done. People with lengthy and severe stenotic segments, on the other hand, are more prone to have ureteral stenting fail. PNS should be considered in such situations.

Exclusion of secondary RPF:

In a patient's medical history, physicians should search for indications of secondary RPF, which might include drugs, viral illness, or cancer. Patients who acquire secondary RPF as a result of malignant disease may or may not have a history of malignant disease; hence, even if no other diseases are present, screening for malignant disease is indicated. A ureteral blockage caused by RPF might be the first sign of a cancerous condition. Serum tumor markers, gastroscopy, and colonoscopy should all be part of the screening process. FDG-PET/CT may be useful in detecting previously undetected primary malignant illness [(19)].

According to early studies, diffusion-weighted MRI may help discriminate between idiopathic RPF and malignant lymphadenopathy, which includes metastatic illness and lymphoma.

There is, however, no well-established radiographic method for distinguishing these illnesses. In ambiguous cases, a histological study is frequently necessary.

Screening for systemic IgG4RD:

Serum IgG4 levels must be evaluated to screen for systemic IgG4RD. FDGPET/CT can be utilized to examine retroperitoneal lesions and detect IgG4RDaffected organs.

Histological evaluation:

To meet the definitive diagnosis criteria for IgG4RD, certain histological abnormalities are required. Furthermore, a good histological evaluation may reveal secondary RPF caused by undetected cancer. Patients with extra retroperitoneal lesions that are appropriate for biopsy, as well as those with unusual radiographic characteristics, should consider RPF biopsy. Because it is less invasive, CT-guided needle biopsy is advised. Retroperitoneal lesions, on the other hand, are notoriously difficult to obtain.

Furthermore, if malignant lymphoma, is the prevalent cause of secondary RPF, the needle biopsy does not deliver sufficient specimens for diagnosis and sub-classification.

Although laparoscopic biopsy yields a more precise and safe tissue sample, fibrous tissue around the aorta that isn't thick enough might be difficult to get. Even though open biopsy is more dangerous, clinicians must not be afraid to do it [(20)].

Idiopathic RPF is distinguished by fibrous tissue and chronic inflammation. Lymphocytes, plasma cells, and macrophages proliferate in fibrous tissue. IgG4RD is distinguished by a high plasma cell density (>10%), a high ratio of IgG4+/total IgG+ plasma cells (>40%), storiform fibrosis, eosinophil infiltration, and obliterative phlebitis [(21)].

Lesions with severe fibrosis may possess a low ratio of IgG4+/IgG+ cells, which makes IgG4RD susceptible to misdiagnosis. In such cases, idiopathic RPF unrelated to IgG4 may be the diagnosis. This study may promote the idea that "IgG4-unrelated idiopathic RPF" and "IgG4RD" are the equivalent condition.



Figure 2: Idiopathic retroperitoneal fibrosis histopathological and imaging findings infiltrated retroperitoneal soft tissue with extensive and uneven fibrosis (asterisk) and an inflammatory infiltration that occasionally forms lymphoid aggregates (arrows). Original magnification: 10. Haematoxylin and eosin b within collagen bundles, there is a diffuse lymphocyte and plasma cell infiltrate. Original magnification: 40. c Haematoxylin and eosin In a patient with idiopathic retroperitoneal fibrosis, computed CT revealed typical muscle-isodense tissue encircling the anterior and lateral sides of the abdominal aorta (arrow). The tumor causes ureteral blockage, and ureteral stents can be seen in the renal pelvis on both sides. The right kidney has a hypoplasic condition. d Computed CT frequently detects peri-iliac tissue (arrow). e, f CT scan of the thoracic aorta and epiaortic artery in a patient with idiopathic retroperitoneal fibrosis (arrows). g FDG-PET indicates an intense accumulation of 18F-FDG around the abdominal aorta during the active phase of retroperitoneal fibrosis [21].

Abdominal ultrasonography is commonly used as a screening test to aid in early diagnosis. RPF usually manifests itself as a well-defined yet irregular hypo- or anechoic mass. Ureterohydronephrosis can occur as a result of ureteral entrapment.

Unfortunately, the test's sensitivity is modest, mainly in the early stages of the Syndrome, at around 25% [22].

Intravenous urography used to be the best way to find out if someone had RPF because of showing where the ureteral blockage was and how bad it was. But this technique isn't very useful right now because it isn't very sensitive or specific if compared to sectional scanning investigations [23].

RPF is currently diagnosed with computed tomography (CT) scan and magnetic resonance imaging (MRI) (MRI). A CT scan will typically indicate RPF as a well-defined, irregular mass with the same density as the psoas muscle in the paraspinal area. It usually starts between the L4 and L5 vertebrae and moves up, affecting the renal hila, or downwards less frequently affecting the organs of the pelvis. Fibrosis encircles the

aorta and inferior vena cava over time and then covers the ureters and lumbar muscles.

The amount of improvement following the injection of a contrast medium is measured in Hounsfield units (HU). This is determined by the level of inflammation. It is more in the early, active phase than in the late, dormant phase, which typically indicates a more favorable treatment response [(23)].

The baseline HU readings and baseline transverse diameter of retroperitoneal tissue, as reported by **Gao *et al.*** [(24)], may be able to predict whether or not the kidneys will improve after one year of taking medicine. When the T1-weighted signal is faint, RPF can be detected by MRI. The T2-weighted signal is weaker in persistent non-active fibrosis than in the early inflammatory stage, because its strength is related to inflammation activity.

Computed tomography and magnetic resonance imaging can be used to measure the amount of fibrosis, how much the surrounding organs are affected, and how active the inflammatory process is (MRI). They do, however, have some big problems, like not being able to tell the difference between benign and cancerous forms of RPF. Some signs, like when the aorta and vena cava move toward the front of the body, when a mass pushes on nearby tissues, when it is in an odd place, or when it has a lobulated or nodular shape, should make you think it is a malicious development. In these situations, the last conclusion must be established on how biopsies look under a microscope [(22)].

It's also important to remember that many RPF patients have other health concerns, such as uropathological blockage and kidney dysfunction, both of which are reasons to avoid using iodinated contrast media. Nephropathy Gadolinium-based MRI contrast agents have been linked to systemic fibrosis (NSF). Nephropathy Systemic fibrosis is a disease that progresses and can be fatal. Internal organ fibrosis, which leads to organ failure, is defined by thick, stiff skin and fibrosis of internal organs such as the lungs, heart, diaphragm, liver, and kidneys. Patients with GFRs less than 30 ml/min/1.73 m2 should avoid gadolinium-based contrast agents, as the greatest danger is for those in the fourth and fifth stages of chronic kidney disease (CKD) [(25)].

PET/CT and positron radiation imaging studies and 18F-fluorodeoxyglucose (FDG-PET) are being utilized more and more to diagnose and measure the activity and size of RPF, as well as how well treatment is working [(26)].

It can help doctors decide things like whether to take out the ureteral stent or lower the dose of immunosuppressants.

Even when there is a significant medical reaction and a gradual decrease in inflammatory markers, imaging studies show that a large number of patients still have a mass. It can be made up of both dead pieces of fibrous tissue and long-term, hidden inflammation. Positron emission tomography with 18F-fluorodeoxyglucose is a good way to find out how active a cell's metabolism is.

This test is not good at telling the difference in-between idiopathical and malignancy-related to RPF [(26)].

In cases of atypical clinical, laboratory, or radiological manifestations that raise suspicion of an underlying malignant cause (especially in an atypical location of the mass), or in centers with little experience with RPF diagnosis where immunosuppressive therapy hasn't worked well enough, a needle biopsy is still required.

Surgical biopsy is still the benchmark among the several methods (open surgical procedure, laparoscopy, fine needle, transcaval, and CT- Image) because it allows for the collection of many deep samples, which makes it less likely, that metastatic cells will be missed [(23)].



Figure 3: Flowchart for idiopathic retroperitoneal fibrosis diagnosis [27]

Idiopathic RPF treatment:

The determination of idiopathic RPF therapy is keeping the kidney functions undamaged. As a result, medical or urological therapy is not required for idiopathic RPF caused by ureteral obstruction. In most cases of idiopathic RPF that produces ureteral obstruction, a favorable prognosis for renal function may be expected, but in certain cases, long-term steroid therapy and urine drainage may be necessary. The ultimate objective of idiopathic RPF therapy, according to urologists, should be to relieve the ureteric obstruction that requires drainage and to quit utilizing steroids [28].

Medical treatment:

It is critical to get medical assistance. As previously stated, glucocorticoid medication is the first-line treatment, although even the approach is not standardized. The dosage of PSL is normally started at 0.6–1 mg/kg/day for 2–4 weeks, then gradually decreased and maintained at 2.5–5 mg/day for Less than 6 months [29].

The S. IgG4 value in IgG4RD is helpful for glucocorticoid dosage management. Extra-peritoneal disease activity that impairs organ function is crucial in individuals with systemic IgG4RD. Depending on the sickness condition, professional rheumatologists should regularly evaluate systemic medical therapy established by radio-graphic conclusions and acute-phase reactants, as well as the IgG4 serum level.

Maintaining dose of glucocorticoids should not be stopped to avoid the recurrence of the disease [30].

Idiopathic retroperitoneal fibrosis is managed with two major objectives in mind: avoiding inflammation and fibrosis, and restoring urinary system patency in the case of complications. The most typical therapy is a mix of urological and systemic therapies. The treatment algorithm for IRF has not yet been made. Corticosteroids, on the other hand, are certainly the first-line therapy. Prednisone is normally started at 0.5–1 mg/kg/day (30–60 mg/day). This dose is often maintained for 4–8 weeks before being gradually reduced to a maintenance dose of 5–10 mg/day. Different authors recommend treatments that last anywhere from one to three years.

The majority of people see symptom improvement within the first two weeks of using the medicine. In laboratory indicators, a drop in ESR and CRP levels, as well as a decrease in creatinine concentration, may be noticed after a few weeks on average.

The majority of patients had at least partial fibrosis regression on the control CT/MRI after 4–12 months of therapy. Recurrence is prevalent (up to 72 percent) despite the high rate of remission (92–100 percent) in patients treated in this manner [31].

Researchers are exploring new immunosuppressive medicines to minimize relapses and lessen the danger of negative side effects concerning long-term usage of

extra dosages of CS. The experiences, on the other hand, are based on the observations of a limited sample of patients.

According to some reports, methotrexate combined with prednisone at progressively lessening the dose may assist patients with repeated relapses to achieve remission, and when used alone at a low level, this drug can help patients maintain remission.

As first-line therapy, prednisone with azathioprine (AZA) or with intravenous/oral cyclophosphamide (CYC) with altered dose protocols might be successful. AZA has also been used successfully to maintain remission.

Tamoxifen (TMX), an anti-inflammatory and anti-fibroblastic medication, could be a reasonable solution to traditional immunosuppression medication; however, it could be less efficacy than CS at reducing fibrosis and preventing recurrence. It has the advantage of being low in toxicity. However, any unfavorable consequences, notably thromboembolic problems, should be considered [(32)].

In recent years, the recurring or intractable form of IRF has been treated using biological treatments. Although the trials only include a small number of rituximab (RTX), infliximab, and tocilizumab treatments, the results outcomes are encouraging.

Rituximab has attracted the attention of researchers looking into IgG4-RD. as it acts as chimeric antibodies that bind to the CD20 antigen on the surface of B lymphocyte cells. The reduction of circulating B lymphocytes, which are the progenitors of IgG4-producing plasma cells, is caused by RTX therapy. It has a remarkable effect on IgG4 concentrations while leaving other IgG subtype levels unaffected. Several types of IgG4-RD, including IgG4-related RPF, showed clinical improvement after treatment with RTX [(33)].

Management by urologists and surgeons:

Urologists and surgeons commonly start by treating ureteral blockage with ureteral stenting or PNS. On the other hand, both ureteral stents and PNS are harmful. PNS has been linked to poor quality of life as well as catheter-related issues like infection, obstruction, and dislodgement, whereas ureteral stents have been linked to bladder irritation, hematuria, encrustation, and febrile UTIs [(34)].

Furthermore, the effectiveness of a ureteral stent for urine evacuation in extrinsic ureteral obstruction remains unclear. Furthermore, a long-term ureteral stent does not always ensure kidney function. We should try to remove the ureteral stent or PNS as soon as possible even though ureteral blockage can be cleared sometimes during glucocorticoid administration. At the time of stent or PNS tube exchange, retrograde or antegrade pyelography should be performed to demonstrate ureter patency. If the ureteral obstruction has been resolved, the ureteral stent or PNS can be removed. 95% of their patients had their ureteral stents removed after steroid therapy.

Improvement in ureteral obstruction in patients who have a ureteral stent in place, on the other hand, might be difficult to measure. The ureteral wall may be irritated by a ureteral stent. It's challenging to utilize retrograde pyelography to confirm urine flow.

Antegrade pyelography, on the other hand, gives a more reliable evaluation of the ureteral disease state in individuals with PNS [(35)].

Summary:

Although our understanding of RPF has vastly increased in recent years, it is still a tough condition to grasp. Many issues, particularly concerning the pathogenesis, remain unanswered. The connection between IRF and IgG4-RD has to be investigated further. Standardized procedures for diagnosing, treating, and monitoring illnesses are also necessary. Despite a surge in reports of non-CS therapy alternatives, there are currently few randomized trials evaluating the effectiveness of various immunosuppressive drugs in large groups of patients. In the coming years, we should be closer to resolving these issues.

Alongside the growth of the IgG4RD knowledge, the concept of RPF was Comprehended and organized. Because appropriate diagnosis is crucial for treatment and therapy, the necessity for histological examination of retroperitoneal lesions may rise. Idiopathic RPF has a fair prognosis for renal function and responds favorably to glucocorticoids. It's vital to remember, nevertheless, that conservative ureteral obstruction therapy reduces QOL while leaving renal function unaffected. Long-term glucocorticoid usage should also be avoided wherever feasible. As a result, in certain situations, surgical treatment such as ureterolysis might be explored, albeit the optimal indication must be decided.

Declarations:

Consent for Publication: I confirm that I am the only author and accept the manuscript for submission

How, the manuscript has only one author?

Availability of data and material: Available

Competing interests: None

Funding: No fund

Conflicts of Interest: The author declares no conflicts of interest regarding the publication of this paper.

References:

1. **Brandt AS, Kamper L, Kukuk S *et al.* (2011*):*** Associated findings and complications of retroperitoneal fibrosis in 204 patients: Results of a urological registry. J Urol., 185:526–531.
2. **Khosroshahi A, Carruthers M, Stone J *et al.* (2013*):*** Rethinking Ormond's disease. Medicine (Baltimore), 92:82–91.
3. **Kermani T, Crowson C, Achenbach S *et al.* (2011):** Idiopathic retroperitoneal fibrosis: a retrospective review

of clinical presentation, treatment, and outcomes. https://doi.org/10.4065/mcp.2010.0663.

4. **Vaglio A, Maritati F (2016):** Idiopathic retroperitoneal fibrosis. J. Am. Soc. Nephrol., 27: 1880–9.
5. **Tanaka T, Masumori N (2020):** Current approach to diagnosis and management of retroperitoneal fibrosis; international Journal of Urology, 27, 387—394.
6. **Brandt AS, Kamper L, Kukuk S *et al. (*2011*):*** Associated findings and complications of retroperitoneal fibrosis in 204 patients: Results of a urological registry. J Urol., 185:526–531.
7. **Vaglio A, Salvarani C, Buzio C *et al. (*2006*):*** Retroperitoneal fibrosis. doi: 10.1016/S0140-6736(06)68035-5. PMID: 16427494.
8. **Kim J, Hwang J, Nam B *et al. (*2018*):*** Mediastinal and retroperitoneal fibrosis as a manifestation of breast cancer metastasis: A case report and literature review. Medicine,97: e11842.
9. **Chen T, Tian L, Fan D *et al. (*2019*):*** Retroperitoneal fibrosis secondary to non-urology carcinomas: a clinical and outcome analysis of 97 cases. Clin. Transl. Oncol. 21: 373–9.
10. **Yachoui R, Sehgal R, Carmichael B *et al. (*2016*):*** Idiopathic retroperitoneal fibrosis: clinicopathologic features and outcome analysis. Clin. Rheumatol., 35: 401–7.
11. **Umehara H, Okazaki K, Masaki Y *et al.* (2012):** A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod. Rheumatol., 22: 1–14.
12. **Lin Y, Chen P, Chen H *et al. (*2010*):*** IgG4-related retroperitoneal fibrosis: the first reported case in a Chinese population. Int. J. Rheum. Dis., 13: e70–3.
13. **Rossi G, Rocco R, Accorsi B *et al. (*2017*):*** Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern. Emerg. Med., 12: 287–99.
14. **Umehara H, Okazaki K, Masaki Y *et al.* (2012):** Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol., 22:21–30
15. **Goldoni M, Bonini S, Urban M *et al.* (2014):** Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: A case-control study. Ann Intern Med., 161:181–188.
16. **Hamdan A, Moeen Z, Tariq H *et al.* (2021):** An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab. https://doi.org/10.7759/cureus.17940
17. **Boyeva V, Alabsi H, Seidman M *et al.* (2020):** Use of rituximab in idiopathic retroperitoneal fibrosis. https://doi.org/10.1186/s41927-020-00140-9
18. **Juan L, Huanan W, Min W *et al. (*2022*):*** Differences of clinicopathological features between IgG4-related and non-IgG4-related idiopathic retroperitoneal fibrosis, International Journal of Rheumatic Diseases, 25(4): 440-446
19. **Thomas N, Alexander M, Samuel D *et al. (*2022*):*** Mixed connective tissue disease and idiopathic retroperitoneal fibrosis: A rare but important association, doi:10.1016/j.eucr.2022.102009, 42: 102009
20. **Brittney J, Robert J, Jonathan F (2021):** Retroperitoneal fibrosis as a postoperative complication following renal transplantation in cats, Journal of Feline Medicine and Surgery, 24(4): 304-310
21. **Massimiliano C, Chiara L, Corinna A *et al. (*2021*):*** State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation, Clinical and Translational Imaging, 9(4): 299-339.
22. **Cronin C, Lohan D, Blake M *et al.* (2008):** Retroperitoneal fibrosis: A review of clinical features and imaging findings. Am J Roentgenol., 191:423–431.
23. **Caiafa R, Vinuesa A, Izquierdo R *et al.* (2013):** Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. Radiographics, 33:535–552
24. **Gao L, Wang H, Xu Y *et al. (*2015*):*** Computed tomography parameters can be used as predictive markers for the improvement of renal function in patients with retroperitoneal fibrosis. Clin Exp Rheumatol., 33:871–876.
25. **Thomsen H, Morcos S, Almén T *et al.* (2013):** Nephrogenic systemic fibrosis and gadolinium-based contrast media: Updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol., 23:307–318.
26. **Nakajo M, Jinnouchi S, Tanabe H *et al* (2007):** 18F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. J Comput Assist Tomogr., 31:539–543.
27. **Fenaroli, P, Maritati F, Vaglio A (2021):** Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Doi:. 23. 10.1007/s11926-020-00966-9.
28. **Yamamoto M, Takahashi H, Shinomura Y (2014):** Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist. Nat. Rev. Rheumatol., 10: 148–59.
29. **Kubo K, Yamamoto K (2016):** IgG4-related disease. Int. J. Rheum. Dis., 19: 747–62.
30. **Yu S, Drucker A, Lebwohl M *et al. (*2018*):*** A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J. Am. Acad. Dermatol., 78: 733–40.
31. **Vaglio A, Palmisano A, Alberici F *et al.* (2011):** Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomized controlled trial. Lancet, 378:338–346
32. **Brandt A, Kamper L, Kukuk S *et al. (*2014*):*** Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int., 93:320–325
33. **Khosroshahi A, Carruthers M, Deshpande V *et al.* (2012):** Rituximab for the Treatment of IgG4-Related Disease. Medicine (Baltimore), 91:57–66.
34. **Lange D, Bidnur S, Hoag N *et al. (*2015*):*** Ureteral stent-associated complications–where we are and where we are going. Nat. Rev. Urol., 12: 17–25.
35. **Iyoki T, Maehana T, Tanaka T *et al. (*2017*):*** Clinical evaluation of diagnostic and treatment protocol of idiopathic retroperitoneal fibrosis incorporating consideration of possible IgG4-related disease. Hinyokika Kiyo, 63: 449–54.